This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Celixir (previously trading as Cell Therapy) is a British pioneer in Regenerative Medicine. Its team of scientists and biotechnology leadership is devoted to discovering breakthrough medicines that aim to change the standard of medical care for patients.

Back to company profile

Financial data drawn from last filed accounts don't necessarily reflect current trading activity. Financials provided by Company Check.

Accounts

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Turnover - - - £0 £0 £0 £0 £639.92k £715.38k £765.11k £664.32k
Cash £0 £157.48k £168.99k £779.29k £52.87k £1.22m £15.87m £9.54m £5.23m £1.79m £871.87k
Increase in Cash - - - £610.3k £-726.41k £1.17m - - - - -

Profit & Loss

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Audit Fees £0 £0 £0 £0 £25k £25k £0 £0 £42.17k £40k £20k
Cost of Sales - - - - - £0 - - £75.4k £170k £0
Depreciation £0 £0 £349 £2.05k £3.39k £8.94k £12.3k £70.39k £277.4k £399.93k £381.78k
Directors Emoluments - - - £97.38k £75.15k £257.82k £874.17k £1.81m £1.52m £770.31k £334k
Dividends - - - - - - - - - - -
Export - - - £0 £0 £0 £0 - - - -
Gross Profit - - - - - £0 - - £639.98k £595.11k £664.32k
Interest Payments - - - - £0 £0 £0 £0 £5.94k £28.52k £10.87k
Operating Profit - - - - - £-1.58m £-3.06m £-4.81m £-6.67m £-5.87m £-2.78m
Pretax Profit - - - £-312.97k £382.67k £-1.58m £-3.04m £-4.77m £-6.63m £-5.85m £-2.77m
Profit after Tax - - - £-429.22k £382.67k £-1.58m £-3.04m £-4.77m £-6.28m £-2.79m £-2.08m
Retained Profit - - - £-429.22k £382.67k £-1.58m £-3.04m £-4.77m £-6.28m £-2.79m £-2.08m
Taxation - - - £-116.25k £0 £0 £0 £0 £351.46k £3.06m £696.35k
Turnover - - - £0 £0 £0 £0 £639.92k £715.38k £765.11k £664.32k
Wages & Salaries - - - £93.46k £227.65k £510.93k £1.29m £3.22m £3.68m £2.25m £1.1m

Balance Sheet

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Intangible Assets £10k £35k £46.08k £7.95k £98.61k £197.7k £407.28k £718.28k £761.44k £720.97k £746.93k
Bank Loans & Overdrafts £3.93k £9.61k £0 £0 £0 £0 £0 £0 £0 £0 £0
Cash £0 £157.48k £168.99k £779.29k £52.87k £1.22m £15.87m £9.54m £5.23m £1.79m £871.87k
Miscellaneous Current Assets £71.99k £0 £0 £0 £0 £0 £0 £0 £351.46k £2.09m £696.27k
Miscellaneous Current Liabilities £0 £19.74k £0 £1.18m £56.21k £587.91k £239.44k £919.56k £1.19m £1.46m £1.19m
Other Debtors £5.22k £5.78k £0 £143.13k £150.36k £43.92k £134.19k £1.53m £1.52m £2.43m £1.95m
Other Long Term Finance £0 £0 £0 £111.76k £6.16k £0 £5 £64 £64 £250.89k £194.15k
Other Short Term Finance £0 £0 £0 £0 £66.77k £6.16k £12.05k £0 £2.44m £2.89m £2.71m
Stock £0 £0 £0 £0 £0 £0 £0 £0 £0 £0 £0
Tangible Accounts £0 £1.4k £1.75k £62.27k £22.44k £18.33k £575.86k £1.78m £2.16m £727.26k £348.6k
Total Current Assets £94.63k £163.26k £168.99k £922.42k £203.24k £1.27m £16m £11.07m £7.1m £6.31m £3.52m
Total Current Liabilities £16.46k £45.29k £87.02k £1.18m £237.69k £859.8k £450.07k £1.09m £3.93m £4.57m £4.01m
Total Fixed Assets £10k £36.4k £47.84k £70.22k £121.05k £216.04k £983.14k £2.5m £2.92m £1.45m £1.1m
Total Long Term Finance £98.35k £170.04k £211.08k £111.76k £6.16k £0 £12.5m £11.22m £10.58m £10.31m £9.64m
Trade Creditors £12.53k £15.94k £87.02k £5.49k £114.72k £265.73k £198.58k £174k £308.63k £219.72k £113.62k
Trade Debtors £17.42k £0 £0 £0 £0 £0 £0 £0 £0 £0 £0

Capital & Reserves

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Profit & Loss Account Reserve £-20.17k £-115.67k £-306.67k £-698.45k £-315.78k £-1.9m £-4.94m £-9.71m £-15.98m £-18.74m £-20.81m
Called up share capital £10k £100k £225.39k £16.96k £16.96k £18.5k £19.88k £19.97k £19.97k £19.97k £19.97k
Revaluation Reserve £0 £0 £0 £0 £0 £0 £0 £0 £0 £0 £0
Shareholder Funds £-10.17k £-15.67k £-81.28k £-302.24k £80.43k £623.71k £4.03m £1.25m £-4.49m £-7.11m £-9.04m
Sundry Reserves £0 £0 £0 £379.26k £379.26k £2.5m £8.95m £10.94m £11.47m £1.15m £1.3m

Cash

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Increase in Cash - - - £610.3k £-726.41k £1.17m - - - - -
Net Cash Flow Before Financing £0 £0 £0 £574.98k £-726.41k £-951.55k £0 £0 £0 £0 £0
Net Cash Flow From Financing - - - £35.32k £0 £2.12m - - - - -
Net Cash Flow From Operations - - - £599.41k £-672.2k £-825.73k - - - - -

Other Financials

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Net Assets £-10.17k £-15.67k £-81.28k £-302.24k £80.43k £623.71k £4.03m £1.25m £-4.49m £-7.11m £-9.04m
Net Worth £-20.17k £-50.67k £-127.36k £-310.19k £-18.18k £426.01k £3.63m £533.89k £-5.25m £-7.84m £-9.79m
Total Assets £104.63k £199.66k £216.82k £992.64k £324.29k £1.48m £16.98m £13.57m £10.02m £7.76m £4.61m
Total Liabilities £114.8k £215.33k £298.1k £1.29m £243.85k £859.8k £12.95m £12.31m £14.51m £14.88m £13.65m
Working Capital £78.18k £117.97k £81.97k £-260.7k £-34.46k £407.67k £15.55m £9.97m £3.17m £1.75m £-491.57k

Ratios

2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Creditor Days 0% 0% 0% 0% 0% 0% 0% 98.97% 157.03% 104.53% 62.25%
Current Debt Ratio -1.61% -2.88% -1.07% -3.91% 2.95% 1.37% 0.11% 0.87% -0.87% -0.64% -0.44%
Current Ratio 5.75% 3.6% 1.94% 0.78% 0.86% 1.47% 35.55% 10.12% 1.81% 1.38% 0.88%
Debtor Days 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Equity In Percentage -10.7% -9.5% -47.6% -30.7% 35.6% 48.5% 24.3% 9.7% -48.5% -101% -233.9%
Gearing -1.01k% -1.15k% -259.7% -37% 7.7% 0% 309.8% 896.1% -235.5% -144.9% -106.7%
Liquidity Ratio Or Acid Test 5.75% 3.6% 1.94% 0.77% 0.85% 1.47% 35.55% 10.12% 1.8% 1.38% 0.87%
Pre Tax Profit Margin 0% 0% 0% 0% 0% 0% 0% -745.17% -926.46% -764.51% -417.38%
Return On Capital Employed 0% 0% 0% 164.3% 441.92% -253.21% -18.4% -38.23% -108.85% -182.98% -459.09%
Return On Net Assets Employed 0% 0% 0% 103.54% 475.77% -253.21% -75.43% -380.81% 147.54% 82.21% 30.66%
Return On Total Assets Employed 0% 0% 0% -31.52% 118% -106.45% -17.91% -35.15% -66.12% -75.35% -60.11%
Sales Or Net Working Capital 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Stock Turnover Ratio 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Total Debt Ratio -11.28% -13.73% -3.66% -4.28% 3.03% 1.37% 3.2% 9.83% -3.23% -2.09% -1.51%